X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Foley Todd | Dir, 10% | P - Purchase | $18.00 | +232,870 | 4,235,403 | +6% | +$4,191,660 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Mpm Bioventures 2018, L.P. | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Gadicke Ansbert | 10% | P - Purchase | $18.00 | +1,112,777 | 10,260,064 | +12% | +$20,029,986 | |||||
2026-01-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $84.33 | -500 | 74,374 | -1% | -$42,165 | ||||||
| DM | 2026-01-12 | OMER | Omeros Corp | Borges David J. | VP, Finance, CAO | S - Sale+OE | $12.52 | -60,000 | 0 | -100% | -$750,915 | |||||
2026-01-12 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $7.16 | -10,321 | 400,104 | -3% | -$73,898 | ||||||
2026-01-12 | VSTM | Verastem, Inc. | Calkins Daniel | CFO | S - Sale | $7.16 | -5,039 | 104,719 | -5% | -$36,079 | ||||||
| D | 2026-01-12 | QURE | Uniqure N.V. | Gut Robert | Dir | S - Sale+OE | $24.62 | -25,613 | 32,342 | -44% | -$630,483 | |||||
2026-01-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $362.87 | -1,510 | 23,192 | -6% | -$547,929 | ||||||
2026-01-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $362.87 | -9,577 | 78,818 | -11% | -$3,475,157 | ||||||
2026-01-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $362.87 | -2,780 | 57,522 | -5% | -$1,008,766 | ||||||
2026-01-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $362.87 | -1,510 | 29,728 | -5% | -$547,927 | ||||||
| M | 2026-01-12 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $367.37 | -3,800 | 21,801 | -15% | -$1,395,992 | |||||
| DM | 2026-01-13 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.50 | -6,500 | 0 | -100% | -$16,253 | |||||
2026-01-12 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $4.35 | +20,000 | 1,161,064 | +2% | +$86,904 | ||||||
2026-01-12 | GLSI | Greenwich Lifesciences, Inc. | Patel Snehal | CEO, CFO, 10% | P - Purchase | $27.54 | +2,900 | 5,602,302 | 0% | +$79,866 | ||||||
2026-01-12 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $32.62 | -16,236 | 639,151 | -2% | -$529,640 | ||||||
2026-01-12 | MLYS | Mineralys Therapeutics, Inc. | Levy Adam Scott | CFO, Secretary | S - Sale | $32.14 | -10,758 | 8,638 | -55% | -$345,723 | ||||||
| DM | 2026-01-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $32.56 | -8,518 | 61,804 | -12% | -$277,339 | |||||
2026-01-09 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.16 | -213 | 55,499 | 0% | -$8,554 | ||||||
2026-01-09 | ALMS | Alumis Inc. | Akkaraju Srinivas | Dir | P - Purchase | $17.00 | +588,235 | 6,345,219 | +10% | +$9,999,995 | ||||||
2026-01-09 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $27.99 | -48,300 | 215,011 | -18% | -$1,351,762 | ||||||
2026-01-09 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $40.78 | -20,000 | 86,418 | -19% | -$815,634 | ||||||
| D | 2026-01-12 | ZYME | Zymeworks Inc. | Hollywood Mark | EVP, COO | S - Sale+OE | $22.67 | -6,120 | 132,913 | -4% | -$138,762 | |||||
| D | 2026-01-12 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $479.51 | -22,500 | 2,648 | -89% | -$10,788,876 | |||||
| D | 2026-01-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $551.24 | -280 | 842,704 | 0% | -$154,348 | |||||
| D | 2026-01-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $522.39 | -24,520 | 842,704 | -3% | -$12,808,957 | |||||
| D | 2026-01-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $550.33 | -240 | 1,111,129 | 0% | -$132,080 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $37.43 | -13,165 | 140,769 | -9% | -$492,766 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $37.43 | -20,533 | 154,514 | -12% | -$768,550 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $37.43 | -36,932 | 350,919 | -10% | -$1,382,365 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $37.43 | -13,548 | 184,174 | -7% | -$507,102 | |||||
| D | 2026-01-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $522.40 | -18,410 | 1,111,129 | -2% | -$9,617,312 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $37.43 | -27,289 | 593,894 | -4% | -$1,021,427 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $37.43 | -66,610 | 2,625,790 | -2% | -$2,493,212 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $37.43 | -11,047 | 156,700 | -7% | -$413,489 | |||||
| D | 2026-01-12 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $37.43 | -21,142 | 176,883 | -11% | -$791,345 | |||||
| D | 2026-01-12 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $169.00 | -19,215 | 591,315 | -3% | -$3,247,349 | |||||
2026-01-09 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $186.19 | -1,887 | 84,907 | -2% | -$351,341 | ||||||
| D | 2026-01-13 | CLNN | Clene Inc. | Matlin David J | Dir | P - Purchase | $6.50 | +33,333 | 477,824 | +7% | +$216,665 | |||||
2026-01-08 | ALMS | Alumis Inc. | Foresite Labs, LLC | 10% | P - Purchase | $17.00 | +411,764 | 10,487,268 | +4% | +$6,999,988 | ||||||
2026-01-08 | ALMS | Alumis Inc. | Foresite Capital Management VI LLC | 10% | P - Purchase | $17.00 | +411,764 | 10,487,268 | +4% | +$6,999,988 | ||||||
2026-01-08 | ALMS | Alumis Inc. | Tananbaum James B. | Dir, 10% | P - Purchase | $17.00 | +411,764 | 10,487,268 | +4% | +$6,999,988 | ||||||
| M | 2026-01-08 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $75.54 | -80,000 | 5,462,909 | -1% | -$6,043,168 | |||||
| D | 2026-01-12 | ZYME | Zymeworks Inc. | Smith Jeffrey T L | EVP, Chief Medical Officer | S - Sale+OE | $22.67 | -9,310 | 26,708 | -26% | -$211,090 | |||||
| D | 2026-01-12 | ZYME | Zymeworks Inc. | Moore Paul Andrew | Chief Scientific Officer | S - Sale+OE | $22.67 | -9,560 | 48,497 | -16% | -$216,759 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Ecor1 Capital, LLC | Dir | P - Purchase | $18.00 | +2,222,222 | 347,305 | -119% | +$39,999,996 | |||||
| D | 2026-01-12 | ZYME | Zymeworks Inc. | Galbraith Kenneth | Chair, CEO | S - Sale+OE | $22.67 | -30,424 | 226,842 | -12% | -$689,819 | |||||
2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $76.45 | -1,034 | 72,693 | -1% | -$79,049 | ||||||
| M | 2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale | $77.02 | -7,348 | 80,141 | -8% | -$565,946 | |||||
2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Klein Matthew B. | CEO | S - Sale | $76.45 | -2,514 | 394,453 | -1% | -$192,195 | ||||||
2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Golden Lee Scott | EVP, CHIEF MEDICAL OFFICER | S - Sale | $76.45 | -866 | 92,428 | -1% | -$66,206 | ||||||
| M | 2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale | $77.06 | -6,347 | 111,312 | -5% | -$489,081 | |||||
2026-01-08 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale | $76.45 | -940 | 121,987 | -1% | -$71,863 | ||||||
| M | 2026-01-08 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $26.23 | -132,500 | 765,188 | -15% | -$3,476,014 | |||||
| M | 2026-01-08 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $25.02 | -13,920 | 148,780 | -9% | -$348,281 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Vida Ventures Ii, LLC | 10% | P - Purchase | $18.00 | +835,000 | 157,387 | -123% | +$15,030,000 | |||||
| M | 2026-01-08 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.59 | -91,374 | 2,309,869 | -4% | -$53,533 | |||||
| D | 2026-01-12 | AKTS | Aktis Oncology, Inc. | Kim Helen Susan | Dir, 10% | P - Purchase | $18.00 | +835,000 | 157,387 | -123% | +$15,030,000 | |||||
| M | 2026-01-08 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $5.70 | -44,975 | 708,587 | -6% | -$256,235 | |||||
| D | 2026-01-09 | QURE | Uniqure N.V. | Kaye Jack | Dir | S - Sale+OE | $27.28 | -6,390 | 20,439 | -24% | -$174,319 | |||||
| M | 2026-01-08 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $1.82 | -1,281 | 1,035,925 | 0% | -$2,336 | |||||
2022-09-19 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $3.69 | +2,700 | 1,457,918 | 0% | +$9,959 | ||||||
| M | 2026-01-07 | ZBIO | Zenas Biopharma, Inc. | Moulder Leon O Jr | CEO | P - Purchase | $16.39 | +100,000 | 2,075,122 | +5% | +$1,639,000 | |||||
2026-01-08 | MNKD | Mannkind Corp | Tross Stuart A | Chief People, Workpl Officer | S - Sale | $6.33 | -47,006 | 985,007 | -5% | -$297,548 | ||||||
| D | 2026-01-07 | NAMS | Newamsterdam Pharma Co N.V. | Davidson Michael H. | CEO | S - Sale+OE | $0.00 | -11,582 | 459,859 | -2% | -$0 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Lizzul Paul F. | Chief Medical Officer | S - Sale+OE | $44.71 | -3,650 | 42,088 | -8% | -$163,192 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Mulroy Dennis | CFO | S - Sale+OE | $44.71 | -2,515 | 21,852 | -10% | -$112,446 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $44.71 | -2,210 | 12,835 | -15% | -$98,809 | |||||
| D | 2026-01-08 | ANAB | Anaptysbio, Inc | Faga Daniel | Pres, CEO | S - Sale+OE | $44.71 | -14,281 | 479,344 | -3% | -$638,504 | |||||
| D | 2026-01-08 | ARDX | Ardelyx, Inc. | Williams Laura A | Chief Patient Officer | S - Sale+OE | $6.98 | -50,000 | 361,563 | -12% | -$348,900 | |||||
| D | 2026-01-08 | EQ | Equillium, Inc. | Tom Penny | Principal Accounting Officer | S - Sale+OE | $1.29 | -6,533 | 0 | -100% | -$8,428 | |||||
2026-01-08 | XERS | Xeris Biopharma Holdings, Inc. | McCulloch Kevin | See Remarks | S - Sale | $8.00 | -15,000 | 1,710,426 | -1% | -$120,000 | ||||||
| D | 2026-01-07 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $331.76 | -664 | 223,106 | 0% | -$220,289 | |||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale | $72.23 | -8,576 | 283,394 | -3% | -$619,444 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Calderaro Charles III | Chief Technical Officer | S - Sale | $72.23 | -3,727 | 49,797 | -7% | -$269,201 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale | $72.23 | -1,965 | 116,867 | -2% | -$141,932 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Moriarty John B | GC | S - Sale | $72.23 | -2,374 | 74,557 | -3% | -$171,474 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $72.23 | -1,974 | 63,832 | -3% | -$142,582 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale | $72.23 | -2,373 | 36,494 | -6% | -$171,402 | ||||||
2026-01-07 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $72.23 | -2,373 | 91,627 | -3% | -$171,402 | ||||||
| D | 2026-01-07 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $85.08 | -44,199 | 17,494 | -72% | -$3,760,577 | |||||
| M | 2026-01-07 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Pres, CEO | S - Sale | $2.25 | -43,500 | 303,721 | -13% | -$97,875 | |||||
2026-01-08 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale | $41.89 | -12,000 | 19,086 | -39% | -$502,680 | ||||||
2026-01-08 | ALT | Altimmune, Inc. | Pisano Wayne | Dir | P - Purchase | $4.08 | +5,000 | 13,498 | +59% | +$20,410 | ||||||
2026-01-07 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $474.99 | -4,500 | 42,293 | -10% | -$2,137,455 | ||||||
| D | 2026-01-08 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.69 | -13,000 | 0 | -100% | -$34,953 | |||||
| D | 2026-01-07 | ERAS | Erasca, Inc. | Garner Ebun | GC, Corp. Sec. | S - Sale+OE | $5.59 | -120,000 | 25,076 | -83% | -$670,812 | |||||
2026-01-07 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -741,272 | 5,925,394 | -11% | -$3,335,724 | ||||||
| D | 2026-01-06 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $35.18 | -20,000 | 1,235 | -94% | -$703,656 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $5.86 | -34,950 | 7,145,951 | 0% | -$204,878 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $5.86 | -8,987 | 155,907 | -5% | -$52,696 | |||||
| M | 2026-01-06 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $5.86 | -10,945 | 193,284 | -5% | -$64,187 | |||||
2026-01-07 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.09 | -328 | 55,712 | -1% | -$13,149 | ||||||
| D | 2026-01-08 | ALKS | Alkermes Plc. | Hopkinson Craig C. | EVP R, D, Chief Medical Office | S - Sale+OE | $30.00 | -5,000 | 61,740 | -7% | -$150,005 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $174.06 | -4,290 | 107,601 | -4% | -$746,711 | |||||
| M | 2026-01-06 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale | $174.22 | -4,642 | 80,506 | -5% | -$808,733 | |||||
| DM | 2026-01-06 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $174.06 | -16,530 | 86,794 | -16% | -$2,877,139 | |||||
| M | 2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | S - Sale | $77.19 | -2,616 | 73,727 | -3% | -$201,919 | |||||
2026-01-06 | PTCT | Ptc Therapeutics, Inc. | Gravier Pierre | CFO | S - Sale | $76.95 | -2,139 | 90,310 | -2% | -$164,596 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |